



Patent Docket P1467R2

17
KJ
8-16-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Mark Sliwowski (as amended) Serial No.: 09/602,812 Filed: June 23, 2000 For: Humanized Anti-ErbB2 Antibodies and Treatment with Anti-ErbB2 Antibodies	Group Art Unit: 1642 Examiner: J. Hunt RECEIVED AUG 07 2002 TECH CENTER 1600/2900 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to: U.S. Patent and Trademark Office, Washington, D.C. 20231-9999 Express Mail Label No. EV073 722 638 US August 1, 2002 Wendy M. Lee
---	---

REQUEST TO CORRECT INVENTORSHIP UNDER 37 C.F.R. §1.48(b)Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This Request to correct inventorship is being made pursuant to 37 CFR §1.48(b).

Deletion of the following originally named inventors: Camellia W. Adams and Leonard G. Presta is hereby requested. The above named inventors' invention is no longer being claimed in the application as amended.

The correct inventor of the amended application is: Mark Sliwowski.

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$130.00 to cover the processing fees for this request as set forth in 37 CFR 1.17(i), and to charge the deposit account for any further fees in regard to this patent application. A duplicate copy of this Request is enclosed for this purpose.

Respectfully submitted,

GENENTECH, INC.

Date: 8/1/02

By:
Wendy Lee
Reg. No. 40,378
Telephone No. (650) 225-1994

09157

PATENT TRADEMARK OFFICE

08/06/2002 NMOHAMM1 00000011 070630 09602812

02 FC:122 130.00 CH

ATCC



RECEIVED

AUG 0, 7 2002

TECH CENTER 1600/2900

10801 University Blvd • Manassas, VA 20110-2209 • Telephone: 703-365-2700 • FAX: 703-

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

APR 23 1999

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 4.02

To: (Name and Address of Depositor or Attorney)

Genentech, Inc.
Attn: Wendy M. Lee
1 DNA Way
South San Francisco, CA 94080-4990

Deposited on Behalf of: Genentech, Inc. (Ref. P712P4C3 and P1467)

Identification Reference by Depositor:

ATCC Designation

Murine/Murine Hybridoma cell line 2C4

HB-12697

The deposit was accompanied by: ___ a scientific description ___ a proposed taxonomic description indicated above.

The deposit was received April 8, 1999 by this International Depository Authority and has been accepted.

AT YOUR REQUEST: ☒ We will not inform you of requests for the strain.

The strain will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strain, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strain.

If the culture should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace it with living culture of the same.

The strain will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the culture cited above was tested April 19, 1999. On that date, the culture was viable.

International Depository Authority: American Type Culture Collection, Manassas, VA 20110-2209 USA.

Signature of person having authority to represent ATCC:

Barbara M. Hailey
Barbara M. Hailey, Administrator, Patent Depository

Date: April 19, 1999